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لقاح عصية كامليت-غريان
هل هو خيار أمثل لعالج الثآليل الفريوسية؟
اأ�سعد قدوري اليا�سني، �سكرية كامل املالكي، جا�سم نعيم الأ�سدي
abstract: Objectives: This study aimed to compare the effectiveness of the bacillus Calmette-Guérin (BCG) 
vaccine with topical salicylic acid (SA) in the treatment of viral warts. Methods: This non-randomised controlled 
trial was conducted at the Al-Sader Teaching Hospital, Basrah, Iraq, from January 2016 to April 2017. A total of 
201 patients with viral warts were injected with an intradermal purified protein derivative. Subsequently, those 
with negative tuberculin test results received an intradermal BCG vaccination, while those with positive results 
underwent conventional treatment with topical SA. Patients were assessed for any signs of improvement at one, 
two and three months. Results: Overall, 190 patients completed the trial; of these, 133 (70%) received the BCG 
vaccine and 57 (30%) were treated with topical SA. Complete response to treatment was observed in 9.8% and 5.3% 
of patients in the BCG and SA groups, respectively (P <0.001). Cure rates were significantly higher for patients with 
genital (22.2% versus 7.7%; P = 0.002) and common warts (8.5% versus 0%; P = 0.001) treated with the BCG vaccine; 
however, the reverse was true for flat warts (12.9% versus 25%; P = 0.041). A binary logistic regression analysis 
indicated that BCG therapy was the only significant independent predictor of positive treatment response (odds 
ratio: 7.56, 95% confidence interval: 3.72–15.36; P <0.001). Conclusion: The BCG vaccine was more effective than 
topical SA for treating viral warts, with the best response noted in the treatment of genital warts, followed by flat 
warts. However, plantar warts demonstrated least response to this treatment.
Keywords: Human Papilloma Viruses; Warts; Immunotherapy; BCG Vaccine; Salicylic Acid; Clinical Trial; 
Treatment Effectiveness.
امللخ�ص: الهدف: هدفت هذه الدرا�سة اإىل مقارنة فعالية لقاح ع�سية كاملني-غريان )BCG( مع حم�ض ال�سالي�سيليك املو�سعي )SA( يف عالج 
الثاآليل الفريو�سية. الطريقة: اأجريت هذه التجربة غري الع�سوائية ذات ال�سوابط يف م�ست�سفى ال�سدر التعليمي بالب�رصة يف العراق، من يناير 2016 
اإىل اأبريل 2017. مت حقن ما جمموعه 201 مري�سا م�سابا بالثاآليل الفريو�سية مب�ستق الربوتني املنقى داخل اجللد، بعد ذلك، تلقى اأولئك الذين 
ظهرت نتائجهم �سلبية لقاح BCG داخل اجللد، يف حني خ�سع اأولئك الذين كانت نتائجهم اإيجابية للعالج املعتاد با�ستخدام SA املو�سعي. مت 
تقييم املر�سى لأي عالمات حت�سن بعد فرتات �سهرو �سهرين وثالثة اأ�سهر. النتائج: اأكمل 190 مري�سًا التجربة منهم 133 مري�سًا )%70( تلقوا 
لقاح BCG وعولج 57 )%30( منهم با�ستخدام SA املو�سعي. وقد لوحظت اأن هناك ا�ستجابة كاملة للعالج يف %9.8 و %5.3 من املر�سى يف 
جمموعتي BCG و SA على التوايل وبفارق معتد به اح�سائيًا )P >0.001(. وكانت معدلت ال�سفاء اأعلى بكثري للمر�سى الذين كانوا يعانون 
من ثاآليل الأع�ساء التنا�سلية )%22.2 مقابل %7.7؛ P = 0.002( والثاآليل ال�سائعة )%8.5 مقابل %0؛ P = 0.001( للذين عوجلوا بلقاح BCG؛ 
يف املقابل، كان العك�ض �سحيًحا بالن�سبة للثاآليل امل�سطحة )%12.9 مقابل %25؛ P = 0.041( كما اأ�سار حتليل النحدار اللوج�ستي الثنائي اإىل 
اأن عالج BCG كان املتنبئ امل�ستقل الوحيد املهم لال�ستجابة العالجية الإيجابية )ن�سبة الأرجحية: 7.56، فا�سل الثقة %95: 15.36-3.72؛ 
P >0.001(. اخلال�صة: كان لقاح BCG اأكرث فعالية من SA املو�سعي يف عالج الثاآليل الفريو�سية، مع مالحظة اأن الإ�ستجابة كانت اأف�سل يف 
عالج الثاآليل التنا�سلية، تليها الثاآليل امل�سطحة بينما اأظهرت الثاآليل الأخم�سية اأقل ا�ستجابة لهذا العالج.
الكلمات املفتاحية: فريو�سات الورم احلليمي الب�رصي؛ البثور؛ العالج املناعي؛ لقاح ع�سوية كامليت غورين؛ حم�ض ال�سالي�سيليك؛ جتربة �رصيرية؛ فعالية 
العالج. 
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clinical & basic research
Advances in Knowledge
- The treatment of viral warts is challenging, with some warts resistant to conventional therapy; however, immunotherapy is a relatively new yet 
promising modality, particularly the bacillus Calmette-Guérin (BCG) vaccine.
- Results from this non-randomised controlled trial indicate that immunotherapy with the BCG vaccine was more effective than conventional 
treatment using topical salicylic acid.
Application to Patient Care
- The results of this trial highlight the effectiveness of the BCG vaccine as an alternative treatment for viral warts. This modality can be simply and 
cheaply implemented into clinical practice.
Asaad Q. Al-Yassen, Shukrya K. Al-Maliki and Jasim N. Al-Asadi
Clinical and Basic Research | e331
Viral warts are common benign skin growths caused by human papilloma virus (HPV) infections.1 Diverse HPV strains are 
responsible for specific types of warts, such as common, 
flat, intermediate, plantar, mosaic, anogenital and oral 
warts.2 In general, warts predominantly affect children 
compared to infants and adults and more frequently 
affect the face and upper and lower limbs.1,3,4 Viral warts 
can proliferate and increase in both dimension and 
quantity; on the other hand, spontaneous remission 
within a two-year period has also been reported.4,5 In 
addition, viral warts often recur and are unresponsive 
to conventional management.4,6 As such, the prognosis 
of individual cases is usually uncertain.
Various modalities exist in the treatment of viral 
warts, including surgical excision, electrocauterisation, 
cryotherapy and laser ablation; however, these options 
are often time-consuming, painful and potentially 
disfiguring.4 Topical salicylic acid (SA), although 
usually readily available and a convenient method of 
treating warts at the focus location, can be irritating 
and is inefficient in cases with numerous warts or 
warts in several sites; moreover, patients must adhere 
to a strict daily application schedule for the treatment 
to be effective.7,8 Optimally, the goal of treatment is to 
eliminate the warts with no subsequent recurrence (i.e. 
lifelong immunity) and without disfiguring the patient; 
however, no single therapy is currently guaranteed to 
cure viral warts and prevent their recurrence.5 This 
has made treatment somewhat of a challenge for both 
dermatologists and patients.
Immunotherapy represents a promising new 
modality for the management of recurring and resistant 
viral warts.9–11 This method can resolve warts without 
physically altering or damaging the surrounding 
tissue; moreover, it enhances the host response against 
the causal agent, leading to widespread resolution 
and diminishing the likelihood of recurrence.6,7 
Although the exact mechanism of its action in 
treating viral warts is not yet completely understood, 
immunotherapy is believed to stimulate a systemic T 
cell-mediated response resulting in resolution both at 
the site of contact and distally.12,13 The objective of this 
study was to compare the effectiveness and safety of 
the bacillus Calmette-Guérin (BCG) vaccine as a form 
of immunotherapy in comparison to conventional 
topical SA application for the treatment of viral warts.
Methods
This non-randomised controlled trial was carried out 
from January 2016 to April 2017 at the dermatology 
outpatient clinic of the Al-Sader Teaching Hospital 
in Basrah, Iraq. All consecutive patients attending 
the clinic during this period with more than five 
clinically-diagnosed viral warts were included in 
the trial. However, immunosuppressed patients and 
those with chronic diseases such as diabetes mellitus, 
vitiligo and lupus or local or systemic inflammation 
were excluded, as were pregnant or lactating women. 
None of the participants had received any recorded 
treatment for warts within the three-month period 
preceding the start of the trial.
Interviews were conducted to collect information 
regarding the patients' age, gender and duration 
of warts; in addition, a clinical examination was 
conducted to determine the type, site and number 
of warts. Subsequently, each patient underwent a 
Mantoux tuberculin skin test in which 0.1 mL of 
purified protein derivative was injected intradermally 
into the left forearm at the volar aspect. Approximately 
48–72 hours later, a trained researcher inspected 
and palpated the skin to determine the presence or 
absence of an induration. In order to standardise the 
results of the test, the diameter of the induration was 
measured to determine the presence (i.e. induration 
of ≥15 mm) or absence (i.e. induration of <15 mm) 
of cell-mediated immunity to tuberculin.14 Based on 
this, patients were assigned to either the BCG group 
if they had negative results or the SA group if they had 
positive results. The former received one intradermal 
dose of the BCG vaccine while the latter underwent 
conventional treatment involving the daily application 
of 15–20% SA in a suitable base. 
Subsequently, patients in both groups were 
followed-up for three months. Clinical evaluation 
and photographic measurement of the lesions were 
performed at baseline before treatment and at one, 
two and three months after treatment. Based on these 
indicators, response to treatment was calculated as 
either a complete response to treatment (defined 
as the total resolution of all warts), partial response 
(defined as a decrease in the number and/or apparent 
size of the warts), mild response (defined as a <25% 
resolution in the number and/or apparent size of the 
warts) or no response (defined as no decrease in the 
number and/or apparent size of the warts). 
Data analysis was performed using the Statistical 
Package for the Social Sciences (SPSS), Version 20.0 
(IBM Corp, Armonk, New York, USA). The results 
were reported using descriptive statistics. Quantitative 
results were presented as means and standard 
deviations while nominal results were presented as 
percentages and frequencies. Differences were assessed 
using Chi-squared or Fisher’s exact tests, wherever 
applicable. Non-parametric Mann-Whitney-U, t 
test and analysis of variance tests were performed 
to compare the means of independent variables. A 
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binary logistic regression analysis was conducted to 
determine independent factors predicting response to 
treatment. For the purposes of the regression analysis, 
response to treatment was dichotomised into either a 
positive response (i.e. complete or partial response to 
treatment) or no response. A P value of <0.050 was 
considered to be statistically significant.
This study was approved by the Ethical 
Committee of the College of Medicine, University 
of Basrah [Code 030407042-2016]. Informed written 
consent was obtained from all participants.
Results
A total of 201 patients were originally enrolled in 
the trial; however, five received only the tuberculin 
injection and another six were lost to follow-up, 
resulting in a final sample of 190 patients (94.5%).
Of these, 129 (67.9%) were male and 61(32.1%) were 
female (ratio: 2.1:1). The mean age was 27.8±8.7 years 
and mean number and duration of viral warts was 20.9 
± 7.3 warts and 9.0±3.7 months, respectively. The face 
was the most common site affected (30.5%), followed 
by the hands (23.7%), upper & lower limbs (20.6%), 
genitalia (14.7%), and neck (2.6%). Multiple sites were 
involved in 7.9% of cases. In terms of wart type, 43.2% 
presented with common warts, while 20.5% had flat 
warts, 16.3% had genital warts, 11.6% had filiform 
warts and only 8.4% had plantar warts.
Based on the results of the Mantoux test, 133 
patients (70%) received the BCG vaccine, while the 
remaining 57 patients (30%) received conventional 
 
Figure 1: Flowchart showing the group allocation and intervention processes applied to the clinical trial.
TST = tuberculin skin test; SA = salicylic acid; BCG = bacillus Calmette-Guérin.
Table1: Comparison of treatment response to the bacillus Calmette-Guérin vaccine or conventional treatment with 
salicylic acid among patients with viral warts (N = 190)
Type of wart Response, n (%) P value
BCG group* (n =133) SA group†(n =57)
Complete Partial None Complete Partial None
Common 5 (8.5) 45 (76.3) 9 (15.3) 0 (0) 4 (17.4) 19 (82.6) 0.001
Flat 4 (12.9) 26 (83.9) 1 (3.2) 2 (25) 4 (50.0) 2 (25) 0.041
Genital 4 (22.2) 13 (72.2) 1 (5.6) 1 (7.7) 4 (30.8) 8 (61.5) 0.002
Filiform 0 (0) 12 (80) 3 (20) 0 (0) 4 (57.1) 3 (42.9) 0.334
Plantar 0 (0) 4 (40) 6 (60) 0 (0) 4 (66.7) 2 (33.3) 0.608
Total 13 (9.8) 100 (75.2) 20 (15) 3 (5.3) 20 (35.1) 34 (59.6) <0.001
BCG= bacillus Calmette-Guérin; SA = salicylic acid.
*χ2 = 25.387; P = 0.002. †χ2= 17.944; P = 0.019.
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treatment with topical SA [Figure 1]. The overall 
cure rate was significantly higher among those who 
received the BCG vaccine compared to those receiving 
conventional treatment (9.8% versus 5.3%; P<0.001). 
Moreover, in the BCG group, rates of partial response 
and non-response to treatment were 75.2% and 15%, 
respectively, compared to 35.1% and 59.6% in the SA 
group. In terms of wart type, complete clearance was 
 
Figure 2: Photographs of the foot sole and toes of a 
patient showing (A) multiple plantar warts before 
treatment and (B) complete clearance two months after 
receiving the bacillus Calmette-Guérin vaccine.
 
Figure 3: Photographs of the fingers of a patient 
showing (A) common warts before treatment and (B) 
complete clearance two months after receiving the 
bacillus Calmette-Guérin vaccine.
 
Figure 4: Comparison of treatment response to the bacillus Calmette-Guérin vaccine or conventional treatment with 
salicylic acid according to number of warts among patients with viral warts (N = 190). The difference between groups 
was statistically significant (P = 0.043).
BCG= bacillus Calmette-Guérin; SA= salicylic acid.
Table 2: Literature review of previous studies assessing use of the bacillus Calmette-Guérin vaccine for the treatment 
of viral warts12,16,22–24













Sharquie et al.12 
(2008)
Intradermal 3 months after 
the last dose
3 4 weeks 39.7% •None
Kenawi et al.22 
(2012)
Intralesional Until CC or 
up to four 
treatment 
sessions
4 3 weeks 40% •Pain, ulcers and 
constitutional symptoms 
(i.e. fever, necrosis and 
lymphadenitis)
Podder et al.16 
(2017)
Intradermal 4 weeks after 
treatment
3 4 weeks 48.5% •Pain during the injection 
and abscess formation and 
scarring at the injection site
Rajashekar et al.23 
(2018)
Intralesional 6 months 4 2 weeks 30.8% • Pain, fever, myalgia and 
flu-like symptoms
Jaisinghani et al.24 
(2019)
Intralesional 3 months 3 3 weeks 73.53% • Pain, flu-like symptoms, 




Intradermal 3 months 1 - 9.8% • Minimal scarring at the 
injection site
CC = complete clearance; BCG = bacillus Calmette-Guérin
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more frequently observed with BCG therapy among 
those with common warts (8.5% versus 0%; P = 0.001) 
and genital warts (22.2% versus 7.7%; P = 0.002), while 
the reverse was true for flat warts (12.9% versus 25%; P 
= 0.041) [Table 1]. 
In both groups, patients most frequently started 
responding to treatment by the second month [Figures 
2 and 3], with a significantly greater response observed 
in the BCG group compared to the SA group (10.5% 
versus 1.8%; P = 0.042). By the third month, 84.9% of 
the BCG group were partially or completely cured 
in comparison to 40.4% of the SA group (P <0.001). 
Moreover, while the rate of response to treatment 
increased alongside the number of warts in both 
groups, the response was significantly greater in the 
BCG group (P =0.043) [Figure 4]. Although the cure 
rate was higher among those with longer disease 
durations (≥10 months) compared to those with 
shorter durations (<10 months), this difference was 
not statistically significant (11.9% versus 8.8%; P = 
0.451).
The binary logistic regression analysis showed 
that BCG therapy was the only significant independent 
determinant of response to treatment (odds ratio: 
7.56, 95% confidence interval: 3.72–15.36; P <0.001). 
All other variables were non-significant, including 
age, gender and the number, site, type and duration 
of the warts. In terms of possible complications from 
treatment, no side-effects were documented in any 
of the patients regardless of group, except for mild 
scarring due to the intradermal injection of the vaccine 
in the BCG group. 
Discussion
Immunotherapies can be administered via topical, 
intralesional or systemic routes, with systemic 
immunotherapy found to be a safe, affordable and 
effective option for multiple intractable viral warts.4,9,15 
Originally, the BCG vaccine was formulated as a 
prophylactic against tuberculosis; however, this 
immunotherapy has since been incorporated in the 
management of other diseases with varying success 
rates, including malignant melanomas, alopecia areata 
and transitional cell carcinomas.16–19 The BCG vaccine 
affects the immune system and offers protection 
against infections—including those viral in origin—
via the stimulation of innate immune memory and 
activation of the heterologous lymphocytes, resulting 
in enhanced cytokine production.20
The current clinical trial aimed to compare two 
methods of treating viral warts—the BCG vaccine as 
a form of immunotherapy and conventional treatment 
with topical SA—in terms of both effectiveness (i.e. 
response to treatment) and safety (i.e. the occurrence 
of any medical complications). The BCG vaccine 
was found to result in a significantly higher rate of 
complete response to treatment compared to topical 
SA (9.8% versus 5.3%). This is potentially because 
immunotherapy is more effective at destroying the 
infected cells by activating a systemic inflammatory 
response; in addition, it removes any potential issue of 
non-adherence to treatment as the vaccine is injected 
by clinicians, while topical treatment is carried out by 
the patients themselves.21  In Iraq, the BCG vaccine 
is provided to all citizens free of charge at primary 
health centres; as such, it is an excellent option for 
low-income patients.
Nevertheless, other studies have reported much 
higher rates of complete clearance with BCG therapy 
(39.7–40%).12,22 Variations in specific treatment details 
might play a role in the rate of complete clearance 
[Table 2].12,16,22–24  The low rate in the present study 
could be due to the shorter duration of follow-up (three 
months) or the fact that patients received only one 
BCG injection via an intradermal route; it is possible 
that some of the partial responses would have cleared 
completely with more time, alternative routes or 
additional BCG injections. Rajashekar et al. observed 
a clearance rate of 30.8% with multiple intralesional 
BCG injections and a longer duration of follow-up 
(six months).23 Another study noted a clearance rate 
of 73.53% using three doses of intralesional BCG 
vaccine.24 Both the intralesional administration and 
the increased number of doses might explain such 
high clearance rates, considering that drug effect is 
a function of both dose and time.25 Indeed, repeated 
BCG injections seem to result in a booster effect or 
dose-response relationship.23,24
In the current study, treatment response was 
found to be linked to greater numbers of warts with 
both types of therapy, although better responses 
were noted in the group receiving the BCG vaccine. 
This is in agreement with results reported by Kenawi 
et al.22 These findings could be explained by the fact 
that patients with larger numbers of warts in the SA 
group might be less likely to comply with a treatment 
regimen which involved the daily topical application 
of SA on each individual wart over a 12-week period; 
in contrast, BCG therapy is much more convenient 
for the patient as it simply involves a single injection 
performed by a clinician and results in the clearance of 
warts from multiple sites. 
Regardless of type of treatment, the best 
responses in the present study were noted for genital 
and flat warts, with plantar warts demonstrating the 
least response. Similar results have been reported by 
other researchers.12,26,27 Genital warts are typically 
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caused by HPV types 6 and 11 which have a low 
risk of inducing intraepithelial dysplasia; this could 
potentially explain better responses to BCG treatment 
for these types of warts.28 In contrast, Youn et al. 
reported that plantar warts exhibited superior cure 
rates with liquid nitrogen cryotherapy compared to 
other types of warts; the authors attributed this to the 
effectiveness of routine paring (i.e. the elimination of 
excessive keratin) before each cryotherapy session.29
Generally, patients in both groups in the current 
study began exhibiting responses to treatment after 
two months. Podder et al. similarly reported that 
clinical results first became apparent four weeks after 
BCG therapy was initiated.16 Moreover, while the 
difference was not statistically significant, cases with 
longer disease duration in the present study appeared 
to exhibit better responses to BCG therapy, but not SA 
treatment. This result is consistent with those obtained 
by Kenawi et al.22 Patients with persistent viral warts 
may demonstrate better enhancement and stimulation 
of immune response with BCG therapy, in which case 
maintaining a healthy immune status could prevent 
recurrence.29 In contrast, Bruggink et al. and Choi 
et al. concluded that longer-lasting warts were more 
difficult to treat with either conventional treatments 
alone (i.e. liquid nitrogen and topical SA) or combined 
with an immunomodulator (dinitrochlorobenzene), 
which they also assumed to be due to an immunity-
related issue.8,21
In the current study, patients with negative 
Mantoux test results were given the BCG vaccine 
to prove its ability to reactivate immunity and, 
consequently, its potential role in the treatment of 
viral warts. Prior to their assignment to the BCG or 
SA groups, all patients in the current trial underwent 
tuberculin skin tests on the assumption that a 
positive Mantoux test would measure the degree of 
hypersensitivity to tuberculin.14 However, the absence 
of an induration (or one under 15 mm in diameter) may 
be due to the lack of previous sensitisation; moreover, 
positive results may indicate intact or persistent cell-
mediated immunity, while negative results could 
indicate a weakened immune system due to a myriad 
of reasons, such as a concurrent viral infection.14,30
The study was subject to certain limitations. 
First, the lack of randomisation in the allocation of 
treatment groups could have resulted in potential 
confounding bias, restricting complete confirmation 
of the causal effect of each treatment. However, such 
confounding was adjusted for by applying multiple 
regression analyses.31 Another limitation was that 
the precise cytokine levels of the patients in the BCG 
group were not measured due to financial reasons. 
Finally, although the diameter of the induration in 
each patient was measured after the tuberculin skin 
test, false-negative results could not be excluded.14,30
Conclusion
Topical SA is widely used as treatment modality in the 
management of cutaneous viral warts. However, the 
results of this clinical trial provide evidence to support 
the efficacy of intradermal BCG therapy over this 
conventional treatment, particularly for common and 
genital warts. However, further randomised controlled 
studies are necessary to support these findings and 
more clearly ascertain the effectiveness of BCG 
therapy in the treatment of viral warts.
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